Suven Life Sciences Share Price

    NSE
    246
    +5.31 (2.47%)
    SUVEN • 30 Jun, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    120.55%

    3Y Annualised Return

    55.23%

    5Y Annualised Return

    44.67%

    The current prices are delayed, login or Open Demat Account for live prices.

    Suven Life Sciences Stock Performance

    1W Return9.22
    1Y Return133.92
    Today's Low241
    Prev. Close240.69
    Mkt Cap (Cr.)5,367.88
    1M Return0.53
    3Y Return280.33
    52-Week High271.72
    Open243.00
    PE Ratio0.00
    6M Return94.99
    Today's High247.95
    52-Week Low102.5
    Face Value1

    Suven Life Sciences Company background

    Founded in: 1989
    Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider.The Company is a clinicalstage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, ProofofConcept (POC) studies.The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process RD, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from projectbased transactions into relationshipbased business.In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to partfinance the companys project for the manufacture of bulk drugs and drug intermediates and meet longterm working capital requirements totalling to Rs 6.43 cr. During 19992000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad.During 200001, the company has registered a most remarkable record. The total sales of the company during 200001 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year.During the financial year ended 31 March 2014, Suvens Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 201415.During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNSbased programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suvens discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management.In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a headlice product with sales potential estimated at US35 million. In 201314, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 201415. During FY2015, Suvens lead clinical candidate SUVN502 has successfully completed Phase 1b clinical trial thus paving the way for the copound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/ each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.During FY15, the Companys main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.During FY2017, the company has spent Rs. 6973 lakhs on innovative RD in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets. During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose.In FY2018, the company has spent Rs 6,390 lakhs on innovative RD in CNS therapies accounting for 10% on sales.The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA.During the FY 20182019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies.In 201819, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN502, Masupirdine. In 201920, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.

    As of 30 Jun, 2025, Suven Life Sciences share price is ₹246.2. The stock opened at ₹243 and had closed at ₹240.7 the previous day. During today’s trading session, Suven Life Sciences share price moved between ₹241.00 and ₹247.95, with an average price for the day of ₹244.47. Over the last 52 weeks, the stock has recorded a low of ₹102.50 and a high of ₹271.72. In terms of performance, Suven Life Sciences share price has increased by 91.8% over the past six months and has increased by 120.55% over the last year.

    Read More
    Suven Life Sciences SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹1,26,16,841 (+94.11%)

    Daily SIP of 25,000 would have become 1,26,16,841 in 1 year with a gain of 61,16,841 (+94.11%)

    View details of Market Depth

    Suven Life Sciences Fundamental

    Market Cap (in crs)

    5,367.88

    Face Value

    1

    Turnover (in lacs)

    455.91

    Key Metrics

    Qtr Change %
    140.15% Gain from 52W Low
    116.6
    Dividend yield 1yr %
    0

    Suven Life Sciences Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Suven Life Sciences Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1.47 Cr
    1.61 Cr
    2.57 Cr
    1.01 Cr
    2.39 Cr
    Suven Life Sciences Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    17.55 Cr
    32.82 Cr
    21.99 Cr
    17.16 Cr
    21.23 Cr
    28.45 Cr
    Suven Life Sciences Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    -43.94 Cr
    -39.12 Cr
    -49.64 Cr
    -28.04 Cr
    -26.54 Cr
    Suven Life Sciences Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    -160.74 Cr
    -105.08 Cr
    -118.27 Cr
    -122 Cr
    -72.15 Cr
    -94.22 Cr

    Suven Life Sciences Result Highlights

    • Suven Life Sciences Ltd reported a 105.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 18.8%.

    • Its expenses for the quarter were down by 19.2% QoQ and 4.6% YoY.

    • The net profit decreased 32.2% QoQ and decreased 4.0% YoY.

    • The earnings per share (EPS) of Suven Life Sciences Ltd declined at 1.2 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Suven Life Sciences

    Promoter
    70.3%
    Foreign Institutions
    0.2%
    Domestic Institutions
    0.1%
    Public
    29.5%
    Promoter
    70.3%
    Foreign Institutions
    0.3%
    Mutual Funds
    1%
    Domestic Institutions
    1.1%
    Public
    28.4%
    Promoter
    70.3%
    Foreign Institutions
    0.3%
    Mutual Funds
    1%
    Domestic Institutions
    1.1%
    Public
    28.3%
    Promoter
    70.3%
    Foreign Institutions
    0.4%
    Mutual Funds
    1%
    Domestic Institutions
    1.2%
    Public
    28.1%
    Promoter
    69.6%
    Foreign Institutions
    0.5%
    Mutual Funds
    1%
    Domestic Institutions
    1.1%
    Public
    28.8%
    Promoter
    69.6%
    Foreign Institutions
    0.5%
    Domestic Institutions
    0.2%
    Public
    29.8%

    Suven Life Sciences Technical Analysis

    Moving Averages Analysis
    246
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    239.70
    10Day EMA
    237.00
    12Day EMA
    236.20
    20Day EMA
    231.60
    26Day EMA
    226.50
    50Day EMA
    205.20
    100Day EMA
    178.00
    200Day EMA
    154.90
    5Day SMA
    238.00
    10Day SMA
    234.10
    20Day SMA
    235.30
    30Day SMA
    232.10
    50Day SMA
    198.20
    100Day SMA
    159.60
    150Day SMA
    150.40
    200Day SMA
    146.70
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    208105 Rs
    208105 Rs
    Week Rs
    216192 Rs
    216192 Rs
    Month Rs
    411505 Rs
    842948 Rs
    245.03
    Pivot
    Resistance
    First Resistance
    249.07
    Second Resistance
    251.98
    Third Resistance
    256.02
    Support
    First Support
    242.12
    Second support
    238.08
    Third Support
    235.17
    Relative Strength Index
    61.54
    Money Flow Index
    69.87
    MACD
    9.69
    MACD Signal
    11.77
    Average True Range
    13.23
    Average Directional Index
    29.75
    Rate of Change (21)
    0.53
    Rate of Change (125)
    91.83

    Suven Life Sciences Latest News

    27 JUN 2025 | Friday

    Suven Life Sciences Ltd - 530239 - Closure of Trading Window

    05 JUN 2025 | Thursday

    Suven Life Sciences Ltd - 530239 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    05 JUN 2025 | Thursday

    Suven Life Sciences Ltd - 530239 - Shareholder Meeting / Postal Ballot-Outcome of EGM

    View More

    Suven Life Sciences Share Price FAQs

    Suven Life Sciences share price is ₹246 in NSE and ₹244.8 in BSE as on 30/6/2025.

    Suven Life Sciences share price in the past 1-year return was 133.91. The Suven Life Sciences share hit a 1-year low of Rs. 102.5 and a 1-year high of Rs. 271.72.

    The market cap of Suven Life Sciences is Rs. 5367.88 Cr. as of 30/6/2025.

    The PE ratios of Suven Life Sciences is 0 as of 30/6/2025.

    The PB ratios of Suven Life Sciences is 6.67 as of 30/6/2025

    The Mutual Fund Shareholding in Suven Life Sciences was 0.01% at the end of 30/6/2025.

    You can easily buy Suven Life Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Suven Life Sciences share price is ₹271.72 and ₹102.5 as of 30/6/2025.

    Please be aware that Suven Life Sciences stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.35
    +14.95 (+1.86%)
    1,500.60
    -14.80 (-0.98%)
    2,001.50
    -13.40 (-0.67%)
    1,601.80
    -6.20 (-0.39%)
    3,462.00
    +20.90 (+0.61%)
    Top Gainers
    6,217.50
    +198.00 (+3.29%)
    820.35
    +14.95 (+1.86%)
    421.50
    +7.00 (+1.69%)
    872.10
    +14.40 (+1.68%)
    326.75
    +3.30 (+1.02%)
    Top Losers
    1,098.90
    -25.40 (-2.26%)
    1,199.20
    -25.90 (-2.11%)
    2,163.50
    -44.40 (-2.01%)
    4,237.10
    -83.20 (-1.93%)
    12,400.00
    -242.00 (-1.91%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -